iRhythm CEO Says Hospitals Are Deferring Zio AT Onboarding Until VitalConnect Is Folded In

Zio AT revenue was flat from a year earlier, and management expects the slowdown to last a quarter or two.

Share
iRhythm CEO Says Hospitals Are Deferring Zio AT Onboarding Until VitalConnect Is Folded In

iRhythm, which sells the Zio patch for monitoring irregular heart rhythms, said new customers are holding off on onboarding Zio AT until the VitalConnect patch it just bought is merged into one platform. CEO Quentin Blackford said on the company's earnings call Thursday that he expects the drag to last a quarter or two.

Flat AT sales, and why

Zio AT revenue was flat from a year earlier in the third quarter, Blackford said, when management had expected growth in line with the overall business. Based on customer feedback, he said, the company believes the miss was in part due to delayed purchasing decisions after the VitalConnect deal was announced.

He separated core accounts from new ones. Existing AT accounts show durable performance, he said, but new accounts do not want to train staff and integrate with a platform that carries only Zio AT, then repeat the exercise a few months later for VitalConnect. "So they're deferring those decisions to onboard until the platform is combined," he said.

Revenue for the quarter was $221.6 million, up 14.9% from a year earlier, according to the company's results. Blackford said the core Zio Monitor business again beat expectations, and that had AT met them, the quarter would have been a nice beat.

Why diligence missed it

A Truist analyst asked why the issue was not caught in diligence. Blackford said management had expected AT to keep slowing but not this much. Closing the deal sooner than planned, he said, led some customers to look at it more critically and wait on onboarding.

iRhythm closed the VitalConnect purchase on October 5, ahead of its earlier expectation of year-end.

Guidance and the timeline

CFO Dan Wilson said full-year 2026 revenue guidance rises to $890 million to $895 million, or 19% to 20% growth. The fourth-quarter outlook includes about $16 million of VitalConnect revenue and assumes Zio AT is flat from the third quarter.

For 2027, Wilson said the organic business is on track for roughly $1 billion, with AT flat versus 2026 and Zio Monitor growing at a mid-teens rate. He put VitalConnect growth off its $65 million run rate at mid to high teens. The company reiterated an adjusted EBITDA margin of at least 15% for 2027.

Blackford told a Bank of America analyst the integrated platform should begin to be available in the middle of the first quarter of next year, and AT should reaccelerate after that. He said the platform would go to a commercial force of about 200 people, against roughly 30 at VitalConnect. Zio MCT, the company's next-generation patch, is expected to go to the FDA in 2027.

The test of Blackford's timeline comes in the middle of the first quarter of next year, when the single platform is due to start arriving.

Sources

More on iRhythm Holdings

All iRhythm Holdings (IRTC) coverage →